Research Genetic Cancer Centre SA, Florina, Greece.
Research Genetic Cancer Centre GmbH, Zug, Switzerland.
J Cancer Res Ther. 2020 Oct-Dec;16(6):1393-1401. doi: 10.4103/jcrt.JCRT_677_19.
Although cisplatin is used for the treatment of more than half of cancer patients, its use is restricted by serious side effects as well as the development of cisplatin-resistant cancer cells, limiting its use. In RGCC we have synthesized an intermediate molecule in an ERK inhibitor synthesis process.
The aim of the study was to evaluate the effects of combined cisplatin plus RGCC molecule treatment on MCF-7 and MDAMB231 breast cancer cell viability, proliferation, ability to form clones and migrate, as well as the effects on cell cycle and gene expression.
Cell viability and proliferation were measured by Crystal violet exclusion dye and MTT respectively. Clone formation and wound healing assays were also used for clone formation and cell migration evaluation. Cell cycle was studied by flow cytometry, expression of genes was evaluated by PCR and protein expression was evaluated by western blot.
It was found that combination therapy decreased cell viability and proliferation, caused growth arrest, decreased cancer cell invasiveness and the ability to form clones as well as perturbed the expression of genes involved in ERK, cell cycle and cell death pathways. Conclusion: Although the exact mechanism of action of the combination therapy remains to be investigated, it was found that it is more effective than cisplatin monotherapy. Our findings could potentially lead to a new therapeutic regime for the treatment of cancer.
虽然顺铂被用于治疗超过一半的癌症患者，但由于其严重的副作用以及顺铂耐药癌细胞的发展，限制了其应用。在 RGCC，我们合成了 ERK 抑制剂合成过程中的一种中间分子。
本研究旨在评估联合顺铂加 RGCC 分子治疗对 MCF-7 和 MDAMB231 乳腺癌细胞活力、增殖、形成克隆和迁移的能力以及对细胞周期和基因表达的影响。
通过结晶紫排除染料和 MTT 分别测量细胞活力和增殖。克隆形成和划痕愈合试验也用于评估克隆形成和细胞迁移。通过流式细胞术研究细胞周期，通过 PCR 评估基因表达，通过 Western blot 评估蛋白表达。
发现联合治疗降低了细胞活力和增殖，导致生长停滞，降低了癌细胞的侵袭性和形成克隆的能力，并扰乱了涉及 ERK、细胞周期和细胞死亡途径的基因表达。
尽管联合治疗的确切作用机制仍有待研究，但发现它比顺铂单药治疗更有效。我们的发现可能为癌症的治疗带来新的治疗方案。
